Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025
Stock Information for Windtree Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.